SEARCH

SEARCH BY CITATION

References

  • 1
    National Cancer Institute. Kidney Cancer Home Page. Available at: http://www.cancer.gov/cancertopics/types/kidney Accessed August 21, 2008.
  • 2
    Motzer RJ, Bander NH, Nanus DM. Renal cell carcinoma. N Engl J Med. 1996; 335: 865-875.
  • 3
    Linehan WM, Pinto PA, Srinivasan R, et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res. 2007; 13: 671S-679S.
  • 4
    Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006; 295: 2516-2524.
  • 5
    Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356: 125-134.
  • 6
    Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356: 2271-2281.
  • 7
    Bommi-Reddy A, Almeciga I, Sawyer J, et al. Kinase requirements in human cells: III. Altered kinase requirements in VHL−/− cancer cells detected in a pilot synthetic lethal screen. Proc Natl Acad Sci U S A. 2008; 105: 16484-16489.
  • 8
    Sabo E, Boltenko A, Sova Y, Stein A, Kleinhaus S, Resnick MB. Microscopic analysis and significance of vascular architectural complexity in renal cell carcinoma. Clin Cancer Res. 2001; 7: 533-537.
  • 9
    Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000; 6: S55-S57.
  • 10
    Rosenberg SA, Yang JC, White DE, et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg. 1998; 228: 307-319.
  • 11
    Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003; 349: 427-434.
  • 12
    Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006; 295: 2516-2524.
  • 13
    Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356: 125-134.
  • 14
    Rini BI, Wilding GT, Hudes GR, et al. Axitinib in patients with metastatic renal cell cancer refractory to sorafenib. J Clin Oncol. 2007; 25( 18 suppl): 5032.
  • 15
    Hutson TE, Davis ID, Machiels JH, et al. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor [abstract]. J Clin Oncol. 2008; 26( suppl). Abstract 5046.
  • 16
    Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon-α, or both in advanced renal-cell carcinoma. N Engl J Med. 2007; 356: 2271-2281.
  • 17
    Motzer RJ, Escudier B, Oudard S, et al. RAD001 versus placebo in patients with metastatic renal cell carcinoma after progression on VEGFr-TKI therapy: results of a randomized, double blind, multicenter phase III study [abstract]. J Clin Oncol. 2008; 26(pt II suppl 18, ): 1009S. Abstract LBA5026.
  • 18
    Sun ME, Ngo L, Genega EM, et al. Dynamic contrast enhancement of renal cell carcinoma using a clinical MR protocol: correlation with pathology. Radiology. 2009; 250: 793-802.
  • 19
    de Bazelaire C, Alsop DC, George D, et al. MRI measured tumor blood flow change following antiangiogenic therapy with PTK787/ZK 222584 (PTK/ZK) correlates with clinical outcome in metastatic renal cell carcinoma. Clin Cancer Res. 2008; 14: 5548-5554.